Downloads

  1. Antibody–Drug Conjugates 3.0: A New Era Of Precision Engineering In Oncology 11/25/2025

    The evolution of ADCs illustrates how advances in antibody engineering, linker chemistry, and conjugation technology can incrementally refine a therapeutic modality.

  2. Challenges And Opportunities For Reducing In Vivo Safety Assessment Testing With New Approach Methodologies 11/24/2025

    Although NAMs — such as organoids, organs-on-chips, MPS, and in silico models — have transformed preclinical science, they still face scientific, technical, and regulatory constraints.

  3. Rethinking The "3:1 Rule" In LNP Production 11/21/2025

    A new two-step, ideal-mixing strategy from MIT researchers shows how operating briefly in unstable regions of LNP assembly can unlock precise control of particle size and shape—advancing next-gen RNA manufacturing.

  4. Extrusion-Based ASD Scale-Up: Performance Through Process Understanding 11/20/2025

    Explore the formulation and manufacturing considerations for amorphous solid dispersions (ASDs), with a focus on hot melt extrusion (HME) as a scalable and cost-effective technology option.

  5. Streamlining pDNA: Capacity, Complexity, And Cutting-Edge Solutions 11/20/2025

    Learn how flexible facility design and process innovation are accelerating pDNA manufacturing, as well as key strategies to avoid scale-up pitfalls and meet growing therapeutic demand.

  6. An End-To-End Automated HTP Platform For Cell Line Optimization 11/20/2025

    Bristol Myers Squibb's high-throughput stable CHO platform produces high-titer, high-quality material in a fraction of the conventional timeline.

  7. Are You Keeping Pace With Oligo Synthesis Optimization? 11/18/2025

    The rapidly expanding oligo market demands optimized RNA synthesis. Examine key innovations and workflow insights to maximize resources and control long-term manufacturing costs.

  8. Why VCs Are Investing In Cheaper "Generic" LLMs For Drug Discovery 11/17/2025

    VCs are looking to invest in cheaper, generic LLMs rather than expensive, customized LLMs in drug discovery.

  9. Powering Production Of Viral Vector-Based Therapies 11/14/2025

    Gene therapies hold immense potential to provide long-lasting treatments for a wide range of diseases. At Cytiva, we offer GMP-compliant, end-to-end manufacturing solutions designed to support the development and commercialization of advanced medicines across multiple modalities – including AAV, adenovirus (AV), lentivirus (LV), plasmid DNA (pDNA) and exosomes. Our dependable suite of technologies and expertise ensures scalability, quality, and regulatory confidence at every stage of your journey.

  10. Comprehensive Suite Of In Vivo And In Vitro Services 11/13/2025

    Accelerate vaccine development with integrated services, supporting all common vaccine types from discovery through IND. Leverage expertise in immunogenicity, dose-response, and efficacy studies.